XZB 6877
Alternative Names: XZB-6877Latest Information Update: 31 Mar 2023
At a glance
- Originator Xuanzhu Biopharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Ovarian cancer; Small cell lung cancer; Triple negative breast cancer
Most Recent Events
- 02 Mar 2023 Preclinical trials in Ovarian cancer in China, prior to March 2023 (Xuanzhu Biopharm pipeline, March 2023)
- 02 Mar 2023 Preclinical trials in Small cell lung cancer in China, prior to March 2023 (Xuanzhu Biopharm pipeline, March 2023)
- 02 Mar 2023 Preclinical trials in Triple-negative-breast-cancer in China, prior to March 2023 (Xuanzhu Biopharm pipeline, March 2023)